Keros Therapeutics, Inc. Presents Clinical Data from its KER-050 Program at the 65th American Society of Hematology Annual Meeting and Exposition

Keros Therapeutics, Inc. announced that it presented additional data from its two ongoing Phase 2 clinical trials of KER-050, one in patients with very low-, low-, or intermediate-risk myelodysplastic...

Related Keywords

San Diego ,California ,United States ,American , ,American Society Of Hematology ,Keros Therapeutics Inc ,Keros Therapeutics ,American Society ,Annual Meeting ,Durable Clinical Benefit ,Findings From ,Ongoing Phase ,Superfamily Signaling ,Markets ,